Ahmad A Tarhini

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Melanoma adjuvant therapy
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue 555, Pittsburgh, PA 15232, USA Electronic address
    Hematol Oncol Clin North Am 28:471-89. 2014
  2. pmc CTLA-4 blockade: therapeutic potential in cancer treatments
    Ahmad A Tarhini
    University of Pittsburgh School of Medicine, Melanoma and Skin Cancer Program, Pittsburgh, PA, USA
    Onco Targets Ther 3:15-25. 2010
  3. ncbi request reprint A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, 5th Floor, Suite 555, Pittsburgh, PA 15232, USA
    J Transl Med 12:19. 2014
  4. ncbi request reprint Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue 555, Pittsburgh, PA 15232, U S A
    Anticancer Res 33:4475-81. 2013
  5. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
  6. pmc Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA 15232, USA
    J Immunother 35:702-10. 2012
  7. doi request reprint Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers
    Ahmad A Tarhini
    Assistant Professor of Medicine University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, RM 555 Pittsburgh, Pennsylvania, USA 1 412 648 6507 1 412 648 6579
    Expert Opin Drug Discov 4:587-603. 2009
  8. ncbi request reprint Tremelimumab: a review of development to date in solid tumors
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Avenue, Fifth Floor, Pittsburgh, PA 15232, USA
    Immunotherapy 5:215-29. 2013
  9. doi request reprint IFN-α in the treatment of melanoma
    Ahmad A Tarhini
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    J Immunol 189:3789-93. 2012
  10. pmc Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
    J Immunother 35:359-66. 2012

Collaborators

Detail Information

Publications43

  1. ncbi request reprint Melanoma adjuvant therapy
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue 555, Pittsburgh, PA 15232, USA Electronic address
    Hematol Oncol Clin North Am 28:471-89. 2014
    ..This article reviews melanoma adjuvant therapy along with the ongoing and planned clinical trials. ..
  2. pmc CTLA-4 blockade: therapeutic potential in cancer treatments
    Ahmad A Tarhini
    University of Pittsburgh School of Medicine, Melanoma and Skin Cancer Program, Pittsburgh, PA, USA
    Onco Targets Ther 3:15-25. 2010
    ....
  3. ncbi request reprint A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, 5th Floor, Suite 555, Pittsburgh, PA 15232, USA
    J Transl Med 12:19. 2014
    ..E1694 tested GM2-KLH-QS21 vaccine versus high-dose interferon-α2b (HDI) as adjuvant therapy for operable stage IIB-III melanoma. We tested banked serum specimens from patients in the vaccine arm of E1694 for prognostic biomarkers...
  4. ncbi request reprint Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue 555, Pittsburgh, PA 15232, U S A
    Anticancer Res 33:4475-81. 2013
    ..A phase I trial consisting of panobinostat (a HDAC inhibitor), carboplatin and etoposide was conducted in patients with lung cancer...
  5. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
    ....
  6. pmc Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA 15232, USA
    J Immunother 35:702-10. 2012
    ..T-reg findings suggest that IFN/treme induced clinically significant antitumor responses by inhibiting CTLA4 suppressive effects on T effectors, and less so by affecting T-reg...
  7. doi request reprint Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers
    Ahmad A Tarhini
    Assistant Professor of Medicine University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, RM 555 Pittsburgh, Pennsylvania, USA 1 412 648 6507 1 412 648 6579
    Expert Opin Drug Discov 4:587-603. 2009
    ..Phase I/II clinical trials have shown PF-3512676 to be well tolerated and to have antitumor activity as a single agent in patients with several types of advanced cancer, and to show promise as a vaccine adjuvant...
  8. ncbi request reprint Tremelimumab: a review of development to date in solid tumors
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Avenue, Fifth Floor, Pittsburgh, PA 15232, USA
    Immunotherapy 5:215-29. 2013
    ..The failure of the Phase III trial in melanoma is examined and factors affecting the possible future clinical development of tremelimumab are also explored...
  9. doi request reprint IFN-α in the treatment of melanoma
    Ahmad A Tarhini
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    J Immunol 189:3789-93. 2012
    ....
  10. pmc Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
    J Immunother 35:359-66. 2012
    ....
  11. pmc Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Ave, Fifth Fl, Pittsburgh, PA 15232, USA
    J Clin Oncol 30:322-8. 2012
    ..We tested the hypothesis that the combination of tremelimumab and interferon alfa-2b acting via different and possibly synergistic mechanisms would overcome tumor immune tolerance and lead to significant and durable clinical responses...
  12. pmc Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin
    Ahmad A Tarhini
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 17:6574-81. 2011
    ..We conducted a multicenter phase II study in patients with inoperable stage III or IV melanoma and no prior chemotherapy...
  13. doi request reprint Neoadjuvant therapy for high-risk bulky regional melanoma
    Ahmad A Tarhini
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Surg Oncol 104:386-90. 2011
    ..This will simplify the evaluation of promising new combinations of agents with HDI to build on the clinical, immunologic, and molecular effect of this therapy for patients with melanoma...
  14. pmc Releasing the brake on the immune system: ipilimumab in melanoma and other tumors
    Ahmad Tarhini
    University of Pittsburgh Cancer Institute, Pennsylvania 15232, USA
    Cancer Biother Radiopharm 25:601-13. 2010
    ..Ipilimumab not only has a novel mechanism of action but demonstrates unique immune-related toxicities that require particular care in their recognition and treatment...
  15. pmc A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Hum Gene Ther 22:336-42. 2011
    ..There were no dose-limiting toxicities reported in all three dosing tiers. It is concluded that the oral administration of MnSOD PL is feasible and safe. The phase II recommended dose is 30 mg...
  16. pmc Clinical and immunologic basis of interferon therapy in melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Ann N Y Acad Sci 1182:47-57. 2009
    ..Research of IFN-alpha in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response...
  17. ncbi request reprint Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers
    Ahmad A Tarhini
    University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Melanoma and Skin Cancer Program, Department of Medicine, UPMC Cancer Pavilion, 5150 Centre Avenue, Room 559, Pittsburgh, PA 15232, USA
    Expert Opin Biol Ther 8:1583-93. 2008
    ..Additional Phase II and III studies in combination with other agents will assess antitumor activity in multiple tumor types as well as attempt to identify patient populations most likely to respond...
  18. ncbi request reprint Oblimersen in the treatment of metastatic melanoma
    Ahmad A Tarhini
    Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, UPCI UPMC Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Future Oncol 3:263-71. 2007
    ..This article reviews the biochemistry, pharmacodynamics and pharmacokinetics, safety and efficacy data related to oblimersen in melanoma...
  19. ncbi request reprint Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer
    Ahmad A Tarhini
    University of Pittsburgh School of Medicine, Melanoma and Skin Cancer Program, 5150 Centre Avenue, 5th Floor Pittsburgh, PA 15232, USA
    Curr Opin Mol Ther 9:505-14. 2007
    ..Phase III clinical trials to confirm the role of tremelimumab in the treatment of metastatic melanoma are ongoing, as are phase II trials in patients with NSCLC and colorectal cancer...
  20. doi request reprint Next generation of immunotherapy for melanoma
    John M Kirkwood
    Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Ave, Pittsburgh, PA 15213 2584, USA
    J Clin Oncol 26:3445-55. 2008
    ..Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States...
  21. ncbi request reprint Cutaneous melanoma: available therapy for metastatic disease
    Ahmad A Tarhini
    Division of Hematology Oncology, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5th Floor, 5150 Center Avenue, Pittsburgh, PA 15232, USA
    Dermatol Ther 19:19-25. 2006
    ..A number of novel therapeutic agents are undergoing active clinical investigation...
  22. ncbi request reprint Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    Nat Clin Pract Oncol 5:2-3. 2008
  23. doi request reprint A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer 113:1632-40. 2008
    ..Previous biochemotherapy regimens for metastatic melanoma have required attenuated dosages of interleukin 2 (IL-2) that may have compromised efficacy...
  24. ncbi request reprint First International Symposium on Melanoma and Other Cutaneous Malignancies
    Ahmad A Tarhini
    Division of Hematology Oncology, UPMC Cancer Pavilion, 5th Floor, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Expert Opin Biol Ther 4:1541-6. 2004
    ..Sessions also included case-based learning and devoted ample time to providing 'how to' information for practising physicians...
  25. ncbi request reprint Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    J Clin Oncol 25:3802-7. 2007
    ..We conducted a phase II trial of high-dose bolus (HDB) interleukin-2 (IL-2) in patients with metastatic melanoma who had experienced progression after biochemotherapy (BCT)...
  26. pmc Immunotherapy of cancer in 2012
    John M Kirkwood
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    CA Cancer J Clin 62:309-35. 2012
    ....
  27. doi request reprint PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines
    Julien Fourcade
    Authors Affiliations Division of Hematology Oncology, Department of Medicine Departments of Immunology and Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Pfizer, Cambridge and Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts and Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland
    Cancer Res 74:1045-55. 2014
    ..Collectively, our findings support the use of PD-1 and Tim-3 blockades with cancer vaccines to stimulate potent antitumor T-cell responses and increase the likelihood of clinical responses in patients with advanced melanoma...
  28. doi request reprint Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer 112:1131-8. 2008
    ..Arsenic trioxide (ATO) cytotoxicity and apoptosis induction has been demonstrated with numerous cancer cell lines, including human melanoma...
  29. ncbi request reprint Interleukin-2 for the treatment of melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, 5th Floor, Pittsburgh, PA 15232, USA
    Curr Opin Investig Drugs 6:1234-9. 2005
    ..Newer, innovative approaches such as IL-2 gene therapy and strategies to ameliorate the toxicity of this agent are now being explored in clinical trials...
  30. doi request reprint Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab
    Ahmad A Tarhini
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 9:e87705. 2014
    ....
  31. pmc Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach
    Diwakar Davar
    Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Clin Dermatol 31:237-50. 2013
    ....
  32. doi request reprint A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 2584, USA
    Cancer 115:859-68. 2009
    ..Phase 1 studies demonstrated evidence of recombinant human IL-18 (rhIL-18)-mediated immunomodulatory and clinical activity, and defined a biologically active dose range...
  33. ncbi request reprint Novel agents in development for the treatment of melanoma
    Ahmad A Tarhini
    Division of Medical Oncology and Hematology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Expert Opin Investig Drugs 14:885-92. 2005
    ....
  34. ncbi request reprint Advances in adjuvant therapy: potential for prognostic and predictive biomarkers
    Diwakar Davar
    Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Methods Mol Biol 1102:45-69. 2014
    ..Current research efforts are centered around discovering predictive/prognostic biomarkers and exploring the options for more effective regimens, either singly or in combination. ..
  35. ncbi request reprint Management of brain metastases in patients with melanoma
    Ahmad A Tarhini
    Department of Medicine and Division of Hematology Oncology, Melanoma Center, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Curr Opin Oncol 16:161-6. 2004
    ..The development of more effective therapies for melanoma brain metastases is a major unmet clinical need and is summarized in this review...
  36. ncbi request reprint Adjuvant high-dose interferon-alpha therapy for high-risk melanoma
    John M Kirkwood
    Division of Medical Oncology, University of Pittsburgh, 200 Lothrop Street, 15123 Pittsburg, Pennsylvania
    Forum (Genova) 13:127-40; quiz 187-8. 2003
    ..We also present selected ongoing trials testing potential future therapies that may prove effective for patients with high-risk resected melanoma...
  37. doi request reprint Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa
    Ahmad A Tarhini
    aDepartment of Medicine, Clinical and Translational Science Institute, University of Pittsburgh bUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania cDana Farber Cancer Institute, Biostatistics and Computational Biology, Boston, Massachusetts, USA
    Melanoma Res 24:150-7. 2014
    ..Studies of the genetic determinants of this response may better discriminate patients more likely to benefit from HDI immunomodulatory therapy. ..
  38. pmc Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Clin Oncol 27:38-44. 2009
    ..We evaluated adjuvant trial E1694 to more precisely define the prognostic significance of serum S100B in patients with high-risk resected melanoma...
  39. pmc Adjuvant therapy for melanoma
    Diwakar Davar
    Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
    Cancer J 18:192-202. 2012
    ..At present, several trials investigating combinations of novel agents with existing immunomodulators are underway...
  40. ncbi request reprint Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma?
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, PA 15213, USA
    Nat Clin Pract Oncol 2:240-1. 2005
  41. pmc ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)
    Ronald S Go
    Authors Affiliations Gundersen Health System Gundersen Medical Foundation, La Crosse, Wisconsin Dana Farber Cancer Institute, Boston, Massachusetts University of Alabama Comprehensive Cancer Center, Birmingham, Alabama and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
    Clin Cancer Res 19:6597-604. 2013
    ..The primary objective was suppression of plasma FGF-2 to within reference range (≤ 7.5 pg/mL)...
  42. ncbi request reprint Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b"
    Ahmad A Tarhini
    Oncologist 11:538-9; author reply 539-40. 2006